Related Experiment Videos
Treatment of membranous nephropathy in the elderly
1Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA. cabrass@u.washington.edu
Abstract:
MN is relatively common in the elderly and can lead to significant morbidity and mortality as a result of complications of the nephrotic syndrome and end-stage renal disease. Some cases of MN may be missed as asymptomatic urinary abnormalities and progressive renal disease may be attributed incorrectly to vascular disease or normal aging. Urinary abnormalities and changes in renal function should be evaluated in the elderly using the same criteria as applied in younger individuals. When MN is diagnosed in an elderly individual, it has the same risks for progression as in younger individuals; thus, therapy for hypertension, hyperlipidemia, edema, and proteinuria should be instituted. When appropriate, elderly individuals should receive immunosuppressive therapy to induce a remission of the nephrotic syndrome and reduce the risk for progressive loss of renal function using criteria similar to younger patients. Most studies show response rates to be comparable in all age groups examined. The only consistent recommendation is to avoid high-dose corticosteroids when possible. Recognize that drug dosages need to be modified and carefully monitored and that the elderly may be particularly prone to side effects and infectious complications of immunosuppressive therapy. Although treatment of MN in the elderly has unique challenges, reducing the need for renal replacement therapy in this population merits special attention. This is a US government work. There are no restrictions on its use.
Insights
Membranous nephropathy (MN) in the elderly requires prompt evaluation and treatment. Early intervention can prevent progression to end-stage renal disease and reduce mortality.
Area of Science:
- Nephrology
- Geriatric Medicine
Background:
- Membranous nephropathy (MN) is common in older adults, often presenting with subtle urinary changes or attributed to aging.
- Complications include nephrotic syndrome and end-stage renal disease (ESRD), leading to significant morbidity and mortality.
Purpose of the Study:
- To emphasize the importance of evaluating urinary abnormalities and renal function in the elderly with MN.
- To outline treatment strategies for MN in elderly patients, aiming to preserve renal function and manage complications.
Main Methods:
- Review of existing literature and clinical guidelines for managing MN in the elderly.
- Comparison of treatment responses and risks between elderly and younger patient cohorts.
Main Results:
- Elderly patients with MN face similar progression risks as younger individuals.
- Therapeutic interventions for hypertension, hyperlipidemia, edema, and proteinuria are crucial.
- Immunosuppressive therapy can induce remission and slow renal function decline, with comparable response rates across age groups.
Conclusions:
- MN in the elderly necessitates prompt diagnosis and management comparable to younger patients.
- Treatment should focus on symptom control, risk factor modification, and judicious use of immunosuppression, avoiding high-dose corticosteroids when possible.
- Careful drug monitoring and management of potential side effects are vital in this population to reduce the need for renal replacement therapy.